Targeted Therapies for Triple-Negative Breast Cancer: Combating a Stubborn Disease.
about
Targeting DNA Replication Stress for Cancer TherapyIn vivo models in breast cancer research: progress, challenges and future directions.AHNAK suppresses tumour proliferation and invasion by targeting multiple pathways in triple-negative breast cancer.Inferring synthetic lethal interactions from mutual exclusivity of genetic events in cancer.Systematic Identification and Assessment of Therapeutic Targets for Breast Cancer Based on Genome-Wide RNA Interference TranscriptomesInfluence of wound fluid on chemotherapy sensitivity in primary breast cancer cells.Identification of recurrent BRCA1 mutation and its clinical relevance in Chinese Triple-negative breast cancer cohort.Targeted therapies in breast cancer: New challenges to fight against resistance.Recent Advances in the Neoadjuvant Treatment of Breast Cancer.Relationship between RUNX1 and AXIN1 in ER-negative versus ER-positive Breast Cancer.DNA repair genes PAXIP1 and TP53BP1 expression is associated with breast cancer prognosis.Metastatic breast cancer: The Odyssey of personalization.BRCA testing within the Department of Veterans Affairs: concordance with clinical practice guidelines.High levels of sphingolipids in human breast cancer.Receptors for Insulin-Like Growth Factor-2 and Androgens as Therapeutic Targets in Triple-Negative Breast Cancer.Nitro-fatty acid inhibition of triple negative breast cancer cell viability, migration, invasion and tumor growth.Combination of palbociclib with enzalutamide shows in vitro activity in RB proficient and androgen receptor positive triple negative breast cancer cells.Delayed Sequential Co-Delivery of Gefitinib and Doxorubicin for Targeted Combination Chemotherapy.A model of dormant-emergent metastatic breast cancer progression enabling exploration of biomarker signatures.Fluoxetine induces autophagic cell death via eEF2K-AMPK-mTOR-ULK complex axis in triple negative breast cancer.Sequential combination of docetaxel with a SHP-1 agonist enhanced suppression of p-STAT3 signaling and apoptosis in triple negative breast cancer cells.New 3-alkylpyridine marine alkaloid analogues as promising antitumor agents against the CD44+/high /CD24-/low subset of triple-negative breast cancer cell line.Predicting and Overcoming Chemotherapeutic Resistance in Breast Cancer.Kernelized rank learning for personalized drug recommendation.The MicroRNA miR-210 Is Expressed by Cancer Cells but Also by the Tumor Microenvironment in Triple-Negative Breast Cancer.Anti-angiogenic treatment promotes triple-negative breast cancer invasion via vasculogenic mimicry.Therapeutic Strategies in Triple-Negative Breast Cancer.Immunotherapeutic interventions of Triple Negative Breast Cancer.Identification of the Thioredoxin-Like 2 Autoantibody as a Specific Biomarker for Triple-Negative Breast Cancer.Five-Part Pentameric Nanocomplex Shows Improved Efficacy of Doxorubicin in CD44+ Cancer Cells.Applications of RNA Indexes for Precision Oncology in Breast CancerUnderstanding the functional impact of copy number alterations in breast cancer using a network modeling approachAssociation Analysis of Somatic Copy Number Alteration Burden With Breast Cancer SurvivalGold nanoparticles-induced cytotoxicity in triple negative breast cancer involves different epigenetic alterations depending upon the surface chargeCEP55 is a determinant of cell fate during perturbed mitosis in breast cancer
P2860
Q26739923-CD3D8F2B-B849-4AA5-837C-8338C7FE0FCAQ33588117-2F3E40F3-323D-4CFE-A4EA-9470F2E0DE6DQ33667940-7640827F-FC34-4BE7-BE8A-E749F651DBFAQ36111892-B6407685-3E7E-485B-B194-2F826DFE7DD3Q36293047-7773D699-1DF8-4274-8D89-294EE177FC68Q37662187-28242D94-973C-4196-A0D2-92BD578EF334Q37693410-F261C1C7-C9DF-4430-8F18-A710B978CD3DQ37743048-BEE62690-4525-4346-8C30-CABB46D1B8AEQ38687392-94224CF6-FBD8-492E-B150-B59FFEFB297FQ38722836-B3F4A17E-9D13-464C-9F74-8DF38E75E709Q38802323-E2FF25B4-80B1-4B8A-A80E-38D23DAB373EQ38901163-7CE24539-1E2E-4E29-94F3-73B504DA0174Q38944992-195C6050-5255-44D2-9AAB-6EF25E612036Q40964594-3A94BFDC-B88D-4B8A-B9BE-0A6D0641307EQ46237958-B8C94A82-74FA-4FC0-8F51-3380965C3CE3Q46257711-00B37A33-BF93-4BD3-8A87-211B6C28E4B5Q47271244-B9962F9B-E0CF-41A6-A855-B12A6683DE02Q47403872-19CF815E-E469-4C0A-87DA-14BB7C015C7CQ47558500-B1092F6D-82B7-41AA-908C-9D16EB39EFD9Q47864344-890F3693-486A-49B8-B2B0-52FE10F102BBQ47867377-59914C91-0F6F-445B-9949-D61F5496D998Q48135914-D0304435-300E-4275-9D46-EBAF03EDFBFFQ49544395-BE2B0F39-E74D-4D55-920E-5E717385B43FQ50419862-F26BD670-1C3A-473E-889B-971273CB2855Q50732901-3DB0A65D-76B6-4590-BDB4-36DFC1721AD8Q51104351-A535EE19-2CD6-470F-8608-A5F8F8A1D4B6Q54640193-363FBF80-DFB5-4B9A-803D-D45B89FB7890Q55257180-9C4A5305-1854-4049-817A-2F948A5885F1Q55343812-C58AD586-9DE1-4B5F-A5EE-5020C6ABB163Q55657196-E83FB1DC-EE7C-4286-A2FA-B7BE8B3A58D3Q57113927-75DBE9C2-8E04-4EDD-AC59-FB37652EFA51Q57198680-51CF77DF-3B65-4D59-9CF4-4C8B1B136F8EQ58592626-342D73F3-DD85-4047-BE20-E36CD2FB2FCBQ58774445-D68FA68E-7DB4-4DC2-A124-769617B42B49Q58779939-70C9D0C9-E335-4A31-B01B-73A7904425CC
P2860
Targeted Therapies for Triple-Negative Breast Cancer: Combating a Stubborn Disease.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Targeted Therapies for Triple-Negative Breast Cancer: Combating a Stubborn Disease.
@en
type
label
Targeted Therapies for Triple-Negative Breast Cancer: Combating a Stubborn Disease.
@en
prefLabel
Targeted Therapies for Triple-Negative Breast Cancer: Combating a Stubborn Disease.
@en
P2093
P1476
Targeted Therapies for Triple-Negative Breast Cancer: Combating a Stubborn Disease.
@en
P2093
Deepak Mittal
Kate Parsons
Kum Kum Khanna
Murugan Kalimutho
P304
P356
10.1016/J.TIPS.2015.08.009
P577
2015-09-22T00:00:00Z